President Donald Trump has unveiled a new tariff timeline targeting generic pharmaceutical imports, giving drugmakers a two-year grace period before duties kick in and then climb sharply in the years that follow.
In a post to Truth Social on July 21, Trump said generic drugs entering the United States will carry a zero percent tariff starting Aug. 1, but only for a two-year stretch. Once that window closes in August 2028, imports will be hit with a 100 percent tariff. A year after that, in August 2029, the rate will double again to 200 percent.
“This is done in order to reshore generic pharmaceutical production into America, with a penalty to those companies that decide not to build plants and equipment within the stated period of time given to them,” Trump wrote, framing the escalating tariffs less as a revenue measure and more as an ultimatum to the industry: relocate manufacturing stateside or absorb punishing costs down the road.
Tuesday’s announcement builds on a policy path Trump has been walking since September 2025, when he first floated 100 percent tariffs on patented, brand-name pharmaceuticals. That plan became official on April 2, 2026, when Trump signed a proclamation invoking Section 232 of the Trade Expansion Act of 1962 to impose the levy on patented drugs. Notably, that April order carved out an exemption for generic medicines though it flagged that Commerce Secretary Howard Lutnick would take another look at the issue within a year. Tuesday’s post effectively delivers on that promise, closing the loophole generics had enjoyed.
Unlike the patented-drug tariffs, which took effect on a compressed timeline, the generic drug policy gives manufacturers a considerably longer runway two full years before duties apply, and three before they hit triple-digit rates. Analysts and drug-industry watchers say that extended timeline is deliberate, intended to give companies enough time to actually break ground on U.S. facilities rather than simply absorb a shock.
The tariff threat lands at a sensitive moment for Canadian pharmaceutical trade. Canadian exports of pharmaceuticals to the U.S. were valued at more than $8.7 billion in 2023, accounting for roughly 3 percent of all American drug imports. A March 2025 analysis estimated that around $3 billion worth of those exports involve drugs with final production based in Canada, and that a 25 percent tariff on that category alone could push up costs on more than 400 different drugs by a combined $750 million.
The dynamic runs both ways: the U.S. remains Canada’s single largest pharmaceutical supplier, providing about 36 percent of the total value of the drugs Canada imports, according to Statistics Canada.
The Canadian Pharmaceutical Manufacturers and Exporters Alliance addressed the looming tariffs in a statement issued July 22, saying it had reviewed the proposed framework for generic drugs but was still waiting on further details from Washington. The group noted that because the tariffs won’t take effect for two years, there should be ample time for “industry and policymakers to further assess implementation details, supply chain implications, and opportunities to support each other’s domestic manufacturing objectives.”
The generic drug tariff news arrives alongside a separate and more immediate trade action against Canada. Trump signed proclamations this week imposing new 50 percent tariffs on a select slate of Canadian goods, covering an estimated 5 percent of total U.S.-Canada trade. Those tariffs are set to take effect Aug. 19 and will touch a range of products, including dairy goods, cement, and animal-derived materials used in pharmaceutical manufacturing.
Taken together, the two moves suggest Canada and the broader generic drug supply chain that runs through it is bracing for a period of prolonged uncertainty, even as the actual financial impact of the new pharmaceutical tariffs won’t be felt for at least two years.
